
|Videos|October 11, 2016
Weighing Quality of Life Improvements in Atopic Dermatitis
Advertisement
Episodes in this series

Panelists Peter L. Salgo, MD; Ed Pezalla, MD, MPH; Jeffrey D. Dunn, PharmD, MBA; and Cheryl Allen, BS Pharm, MBA, highlight the triggers to seek clinical care and the direct and indirect costs associated with the disease.
Advertisement
Related to this article

Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.

EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.

Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.

Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.

Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.

Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.

At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
5




















